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Abstract
Purpose—C4, a cobalt dichloride–N-acetyl cysteine complex, is being developed as a positivesignal magnetic resonance imaging (MRI) marker to localize implanted radioactive seeds in
prostate brachytherapy. We evaluated the toxicity and biodistribution of C4 in rats with the goal of
simulating systemic effects of potential leakage from C4 MRI markers within the prostate.
Methods—9 µl doses (equivalent to leakage from 120 markers in a human) of control (0.9%
sodium chloride), 1% (proposed for clinical use) and 10% C4 solution were injected into the
prostates of male Sprague-Dawley rats via laparotomy. Organ toxicity and cobalt disposition in
plasma, tissues, feces and urine were evaluated.
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Results—No C4-related morbidity or mortality was observed in the biodistribution arm (60 rats).
Biodistribution was measurable following 10% C4 injection: cobalt was cleared rapidly from
periprostatic tissue; mean concentrations in prostate were 163 µg/g and 268 µg/g at 5 and 30
minutes but were undetectable by 60 minutes. Expected dual renal-hepatic elimination was
observed with % injected dose recovered in tissues of 39.0 ±5.6% (liver) > 11.8 ±6.5% (prostate)
> 5.3 ±0.9% (kidney) with low plasma concentrations detected up to 1 hr (1.40 µg/ml at 5–60
minutes). Excretion in urine was 13.1 ±4.6 % with 3.1 ±0.54 % recovered in feces by 24 hours. In
the toxicity arm, three animals died in the control group and 1 each in the 1% and 10% groups
from surgical or anesthesia-related complications; all others survived to scheduled termination at
14 days. No C4-related adverse clinical signs or organ toxicity was observed.
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Conclusion—C4-related toxicity was not observed at exposures at least 10-fold that proposed
for human use. This data demonstrating lack of systemic toxicity with dual routes of elimination in
the event of in-situ rupture suggests C4 warrants further investigation as an MRI marker for
prostate brachytherapy.
Keywords
prostate brachytherapy; encapsulated contrast agent marker; C4; magnetic resonance imaging
(MRI); C4 MRI Marker; post-implant dosimetry

INTRODUCTION
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Brachytherapy is a standard-of-care approach for treating localized prostate cancer.
Dosimetric precision after brachytherapy seed implantation is crucial to ensure the adequacy
of the implant and the highest probability of cancer cure.1 For example, if post-implant
evaluation reveals that the radiation dose being delivered to the sites of biopsy-positive
disease is inadequate, additional seeds could be implanted in the prostate to optimize that
patients treatment. MRI is the optimal imaging modality for quality assurance in prostate
brachytherapy. MRI sequences have been identified which reduce susceptibility artifacts for
prostate delineation and provide the best visualization of the anatomy of the prostate and its
surrounding normal tissue structures.2 However, use of MRI for image-based dosimetry
after seed implantation is complicated by the appearance of the titanium radioactive seeds as
signal voids with susceptibility artifacts, making precise localization of each seed within the
prostate and periprostatic tissue difficult.3 CT is still required for fusion with MRI to
distinguish seeds from spacers and to assist with identification of extraprostatic seeds during
post-implant dosimetric evaluation.2 There are inherent problems in the accuracy of MR-CT
fusion however, which subjects the patients to additional radiation exposure and the
inconvenience of additional testing. One approach to ensuring the precise localization of
each seed using MRI alone involves attaching a positive contrast marker to each seed that is
easily visualized by MRI (Fig. 1). The use of an MRI marker could eliminate the need for
CT as part of post-implant assessment and reduce the time for radiation oncologists and
physicists to fuse MRI to CT to identify seeds by CT imaging.
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Over the past 5 years, our group has developed an MRI marker (C4), an encapsulated
contrast-agent incorporating 1% cobalt-dichloride-N-acetyl cysteine (CoCl2-NAC), that
when placed adjacent to radioactive seeds permits precise identification of implanted
radioactive seeds using MRI. When hydrated, cobalt chloride (CoCl2 • 6H2O) has
paramagnetic properties that make it an effective positive contrast agent marker for MRI.
The efficacy of this marker for this purpose was recently demonstrated in an ex vivo4 and invivo canine model (Fig. 2). We further showed that the C4 MRI marker does not affect the
anisotropy of the radioactive seeds and therefore can be placed next to the titanium seeds for
post-implant identification on MRI.5 In the current study, we evaluated the local and
systemic toxicity of C4, as well as the biodistribution of cobalt, in a model mimicking
leakage of C4 solution from MRI markers into the prostate or periprostatic tissue. Using this
model, we were able to investigate the potential for toxicity from possible in situ rupture of
the MRI markers and provide initial insight into the safety of this approach and the
distribution and elimination of cobalt following systemic exposure to C4.

METHODS AND MATERIALS
This study was conducted with strict adherence to the National Research Council’s Guide
for the Care and Use of Laboratory Animals. All methods were reviewed and approved by
the Institutional Animal Care and Use Committee. The study involved tissue distribution and
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toxicity analyses in 8- to 12-week-old male Sprague Dawley rats (supplied by Harlan
Laboratories) after intraprostatic injection of control solution or one of two dosages of C4.
Rats used for toxicity analyses were sexually mature males (i.e., at least 10 weeks old) at the
time of dosing.
Dosing
C4 solutions were freshly prepared on the day of administration. Cobalt chloride
hexahydrate (CoCl2 • 6H2O) and N-Acetyl-Cysteine (NAC, C5H9NO3S) were purchased
from Sigma-Aldrich. 1% C4 solution (1% CoCl2-2% NAC) was prepared by dissolving 0.42
mmol CoCl2 • 6H2O and 1.18 mmol of NAC in 10 mL distilled water. 10% C4 solution
(10% CoCl2-2% NAC) was prepared by dissolving 4.2 mmol CoCl2 • 6H2O and 1.18 mmol
of NAC in 10 mL distillated water. Solutions were sonicated at room temperature for 15
minutes to completely dissolve. Adequate amounts of each solution were retained for
quantification of total cobalt content by inductively coupled plasma analysis. All solutions
were within 10 % of nominal concentrations.
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On study day 0, the rats were anesthetized with isoflurane and either control or C4 solution
was injected into the prostates of each rat through a 1.0-cm incision in the abdominal wall
(laparotomy) in the inguinal region adjacent to the ventral prostate. The injection volume (9
µL) and administration site (the ventral and lateral lobes of the prostate) in rats were selected
to mimic the conditions experienced if all marker seeds implanted in the center and outer
capsule of prostate in a human subject were to rupture simultaneously. The outer dimensions
of the MRI marker are 5.5 mm×0.8 mm, therefore, assuming a maximum active length of
5.5 mm and 0.4 mm radius, the total volume of C4 solution in each MRI marker would be
2.5 µL. For a typical implant of 80–120 titanium seeds, a maximum of 300 µL of 1% C4
could seep into the interstitial space surrounding the prostate, which typically weighs about
60 g in human males. For this rat model we extrapolated the dose to a 0.16-g rat prostate if
120 markers were used and filled to their capacity volume of 2.5 µL [300 µL 1% C4 in 60-g
human prostate = 0.8 µL 1% C4 in 0.16- g rat prostate] and tested doses of 9 µL of 1% (21 µ
g) or 9 µL of 10% C4 complex given as a periprostatic injection, thus exceeding the
maximum amount that could be released in the event of marker rupture in a human by
factors of 10 and 100, respectively.
Biodistribution
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Sixty male rats were divided into 3 groups: 20 underwent intraprostatic injection of control
solution, 20 of 1% C4 solution, and 20 of 10% C4 solution. Rats were weighed upon arrival
and before dosing, and all rats were observed for any signs of toxicity during the entire
course of the in life phase. Five rats from each dose group were euthanized at 5 minutes, 30
minutes, 60 minutes, or 6 hours after dosing and blood samples collected by cardiac
puncture were placed into heparinized tubes, after which the plasma was separated and
frozen at −80°C until analysis. Spleen, heart, brain, prostate, lung, kidney, liver, and gut
from all animals were harvested, blotted, and weighed. Tissue samples from each organ
were placed in cryotubes and frozen at −80°C until analysis; prostate, kidney, liver, and
plasma samples were evaluated immediately, and other tissues were archived. In a separate
cohort, an additional 3 rats were given the highest dosage (10% C4) and maintained
individually in metabolic cages for collection of urine and feces. Urine and feces were
collected during the 24 hours before dosing and at 60 minutes, 6 hours, and 24 hours after
dosing. Urine volume and fecal weight of each collection were recorded and the samples
frozen at −80°C for analysis.
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Thirty male rats were used for toxicity evaluation, 10 received intraprostatic injection of 9
µL control solution, 10 of 1% C4, and 10 of 10% C4. Clinical observations were recorded at
baseline and twice daily thereafter; rats were weighed at baseline, twice weekly (at least 2
days apart) thereafter, and terminally before blood collection and necropsy. Five rats were
sacrificed per group at 24 hours (acute phase) and 14 days (recovery phase) after dosing.
Rats were anesthetized and weighed before and after terminal blood collection via cardiac
puncture for clinical pathology, and a complete necropsy was performed on all animals.
Animals that appeared moribund before their scheduled time for termination were
anesthetized and subjected to the same procedures. Organs were fixed in 10% neutral
buffered formalin for microscopic analysis. Male accessory sex glands (seminal vesicles,
coagulating glands, ventral, lateral and dorsal prostate, ampullary glands and bulbourethral
glands) were collected together, and urinary bladder, urethra and penis were collected
together; these sets of organs were each attached to a small piece of dry cardboard before
immersing into formalin in order to preserve the normal anatomical orientation of the
organs. The testes and epididymides were collected separately. These tissues were fixed in
10% buffered formalin along with the other organs.
Histopathology
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All major organs (40 tissues) of the digestive, urinary, respiratory, cardiovascular,
hematopoietic (including bone marrow assessed via the sternum and femur/knee joint),
endocrine, nervous, musculoskeletal, skin, and reproductive systems, and the site of
abdominal laparotomy were examined grossly and collected in 10% neutral buffered
formalin at necropsy. Formalin fixed tissues were processed, embedded in paraffin blocks,
sectioned, and mounted on glass slides which were stained with hematoxylin and eosin
(H&E), and examined microscopically. Any tissues not processed to slides were archived
for later processing if necessary. The formalin-fixed seminal vesicles, coagulating glands,
and urinary bladder were separated from the reproductive tract and processed together in one
paraffin block. The prostate (ventral lateral and dorsal lobes) and attached genital organs
were sectioned in a transverse (dorsoventral) plane and were processed in a separate paraffin
block.

RESULTS
Biodistribution
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All rats in the biodistribution group survived to their scheduled terminations, with no
morbidity or mortality noted. Low endogenous cobalt concentrations (0.03–0.06 µg/g tissue)
were detectable only in liver tissue in control animals receiving saline. In rats given 1% C4,
cobalt could be measured in the prostate tissue in 2 of 5 animals and only at 5 minutes, and
was not detected in the plasma or kidney (Table 1). Due to largely undetectable
concentrations observed in other tissues at 1% C4, only control and high dose (10% C4)
liver samples were analyzed. Cobalt distribution was evaluable in rats receiving 10% C4,
with a total percent of injected dose recovered of 80.8 % (Table 2). Mean cobalt
concentrations measured in prostate tissue following 10% C4 injection were 163.6 µg/g and
268.6 µg/g at 5 and 30 minutes, but were undetectable in most animals by 60 min post
injection. Plasma cobalt concentrations at 5 to 60 minutes after injection of 10% C4 were a
mean of 1.40 µg/mL and undetectable by 60 minutes. The greatest amount of cobalt was
detected in the liver (39.0 ±5.6 % of injected dose), with 5.3 ± 0.9 % recovered in the
kidney. Concentrations in liver and kidney were half their peak concentration at 30 minutes
(3.4 µg/g) by 6 hours (1.4–1.5 µg/g).
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The percent excreted in the urine by 24 hours post injection was 13.1 ±4.6 %, with 3.1 ±0.5
% recovered in the feces (Table 2). After injection of 10% C4, cobalt was detected in the
urine within 60 minutes, with mean peak concentrations in urine of 11.6 µg/ml at 6 hours.
Cobalt concentrations were negligible in the urine and feces samples collected from 3 rats
the day before injection; only one rat had detectable fecal levels (0.46 µg/g) at 6–24 hours
before injection. Feces were not available for collection at 60 minutes and 6 hours after
injection (likely secondary to surgical manipulation or anesthesia), but mean cobalt
concentration in feces collected 6–24 hours after injection was 3.28 µg/g, indicating that
fecal elimination was 8 times higher after dosing than in normal turnover. These findings are
consistent with the reported main storage sites for cobalt and dual routes of hepatic and renal
elimination.20
Toxicity
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No test article-related morbidity or mortality was noted in the 30 rats tested for toxicity,
although three rats in the control group, one in the 1% group, and one in the 10% group died
of surgery-and/or anesthesia-related causes. All other animals survived to their scheduled
terminations. The single intraprostatic injection of control solution, 1% C4, or 10% C4 did
not result in any toxicologically-important changes in the hematologic (Table 3) or clinical
chemistry (Table 4) parameters, either at day 1 or at day 14 after intraprostatic
administration. All group mean values were within the normal reference range for these
animals. Serum transaminase values were falsely elevated in one rat in the control group and
two rats in the 10% group at study day 14 due to hemolysis of the blood samples. These
three rats had no significant histologic changes observed in the liver that would support
hepatocellular injury or compound toxicity. Similarly, no gross or microscopic lesions
attributable to C4 were detected in any of the examined tissues at either 1 day or 14 days
post administration. Non C4-related inflammatory lesions consistent with reactions related
to surgical manipulation and tissue injection were observed in the connective tissue
surrounding the prostate glands, bladder, epididymides, testicles, and surgical margins of the
skin, abdominal wall, and peritoneum in both the control and treated animals with similar
incidence. Splenic lymphocytic hyperplasia and extramedullary hematopoiesis were also
observed in the control and treated animals that were consistent with immunohematologic
reactions due to chronic inflammation of the surgical site and not related to the test article.
No differences in mean terminal body weights or organ weights (relative to body weight)
were detected among groups at either 1 day or 14 days after the intraprostatic injection.

DISCUSSION
NIH-PA Author Manuscript

To our knowledge, this is the first study to analyze the biodistribution and toxicity of C4.
Even with direct injection of the material into the prostate and surrounding tissues at doses
10 to 100- fold that proposed to be used in humans, no C4-related morbidity or mortality
was observed. The greatest amount of cobalt was detected in the liver (39.0 ±5.6 % of
injected dose), with 5.3 ±0.9 % recovered in the kidney tissue and 13% excreted in the urine;
confirming that this conjugate was eliminated via the kidneys and liver. No C4-related
alterations were noted in the hematologic or clinical chemistry parameters, and no
histopathologic lesions related to C4 administration were detected in rats at either of the
tested dose levels.
The lack of evidence of toxicity from cobalt at the concentrations and volume used in this
study is not surprising. Cobalt is an essential element and an important component of
vitamin B12 (cyanocobalamin), which is required to maintain good health in animals and
humans.7 Vitamin B12 is also a component of enzymes involved in hematopoiesis, and
cobalt deficiencies can lead to pernicious anemia.8 Cobalt chloride is added to animal feed
as a nutritional dietary supplement and is generally recognized as safe at levels consistent
Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2014 March 15.
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with good feeding practices.7 The average person consumes about 11 µg of cobalt per day
from dietary sources, and the U.S. recommended dietary allowance for vitamin B12 for
adults is 2.4 µg/day, which contains 0.1 µg of cobalt.7, 8 According to reports from the U.S.
Department of Health and Human Services and the United Kingdom National Poisons
Information Service on the toxicological profile of cobalt, neither genotoxicity nor
carcinogenicity has been reported in humans from cobalt chloride.7, 9
Excessive cobalt concentrations, however, could be harmful.10 In the 1960s, some breweries
added cobalt salts to beer to stabilize the foam, resulting in exposures of 0.04–0.14 mg
cobalt/kg per serving.11 To date, this is the only information available for intermediateduration exposure via oral ingestion in humans.7 The most sensitive endpoint after oral
exposure to cobalt in humans seems to be an increase in erythrocyte numbers
(polycythemia).10 Davis and Fields reported 16%–20% increases in erythrocyte levels in all
six healthy men given cobalt chloride orally at about 1 mg Co/kg-day.10 However, giving
daily doses of cobalt chloride to pregnant women for 90 days did not prevent the expected
reductions in hematocrit and hemoglobin levels associated with pregnancy.12 In this study,
no evidence of hematologic toxicity was observed. All hematologic parameters remained
within normal range for this species and no abnormalities were observed in the bone
marrow.
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In a further effort to reduce the potential body burden of cobalt should the MRI markers be
compromised inside a patient, we chelated the salt solution to NAC.13 CoCl2 is a hypoxiamimetic and NAC is a reactive oxygen species scavenger.14 NAC is used as a chelating
agent to reverse heavy metal poisoning because of its ability to safely chelate metals such as
cobalt and assist in their elimination.14, 15, 16, 17 Chelation of NAC with CoCl2 results in the
formation of an inert compound with no known biological activity. Several studies have
investigated the effectiveness of various chelating agents for mitigating the toxicity of
cobalt,15, 16, 18 and NAC was found to be the most effective chelator because it increased
both urinary and fecal excretion of cobalt as well as decreased the levels of cobalt in the
liver and spleen.15
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For intermediate-duration oral exposure (<365 days) to cobalt, a minimal risk level has been
derived of 0.01 mg Co/kg-day by dividing the low-observed-adverse-effect-level (1 mg Co/
kg-day) by an uncertainty factor of 100 (10 for use of a low-observed-adverse-effect-level
and 10 for human variability). Therefore, for a standard 75-kg male, the daily allowable
cobalt consumption would be 0.75 mg/day.7 If an individual MRI marker were to be
compromised after implantation, the amount of cobalt released would be 375 times lower
than the daily minimal risk level. Comparing oral exposure levels with bolus injection into
the prostate may be less than optimal, however, at this time, adequate studies are not
available on the chronic toxicity of systemically ingested cobalt or cobalt compounds in
humans and animals. Additional studies including evaluation of stability, the potential for
promotion of reactive oxygen species formation, and the biocompatibility of C4 are ongoing
to further evaluate its safety and to support its use for brachytherapy seed localization.

CONCLUSIONS
This study represents the first to evaluate the biodistribution and local and systemic toxicity
of C4, a novel MRI visible marker under development for use in prostate brachytherapy.
The lack of demonstrated toxicity coupled with rapid elimination as observed in this model
mimicking systemic exposure to C4 provides evidence that it may be a viable candidate as
an imaging marker to improve the accuracy of MRI-based dosimetry.
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Figure 1.

The C4 solution is placed within a polymer (Polyether ether ketone or PEEK) that is the size
of a standard spacer used in strands for prostate brachytherapy. The C4 MRI markers are
visualized within strands adjacent to the titanium non-radioactive seeds in a prostate
phantom under MRI (oblique view)
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Figure 2.

A strand of C4 MRI markers with titanium non-radioactive seeds are placed within an invivo canine prostate and visualized under MRI (sagittal view).
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Table 1

Plasma and Tissue Cobalt Concentrations (Mean ±SD)
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Cobalt [µg/mL]
Plasma
(µg/mL)

Prostate
(µg/g)

Liver
(µg/g)

Kidney
(µg/g)

Control
5 min

nd

nd

0.03 ±0.004

nd

30 min

nd

nd

0.04 ±0.01

nd

60 min

nd

nd

0.06 ±0.03

nd

6 hr

nd

nd

0.06 ±0.04

nd

5 min

nd

17.3 ±7.0

na

nd

30 min

nd

nd

na

nd

60 min

nd

nd

na

nd

6 hr

nd

nd

na

nd

1% C4

10% C4

NIH-PA Author Manuscript

5 min

1.3 ±0.2

163.6 ±141.6

2.1 ±0.7

2.1 ±0.6

30 min

1.4 ±0.4

268.6 ±500.1

3.4 ±1.1

3.4 ±1.0

60 min

1.5 ±--

30.9 ±--

1.9 ±1.0

2.0 ±1.5

--

--

1.5 ±0.7

1.3 ±0.3

6 hr

nd= not detected or below the limits of quantification; minimum detection limit 0.004 µg/ml na = not analyzed
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nd

4.0 ±4.7

4.0 ±0.5

nd

4.6 ±1.1

6 hr

2.1 ±0.8

4.3 ±1.1

3.4 ±4.3

15.1 ±3.1

3.1 ±0.5

4.5 ±1.4

24 hr

1.4 ±1.1

4.5 ±--

2.0 ±--

7.9 ±4.3

60 min

0.8 ±0.5

nd

nd

6.3 ±2.8

6 hr

nd = not detected or below the limits of quantification; minimum detection limit 0.004 µg/ml

3.1 ±0.5

Feces

1 hr

Total

13.1 ±4.6

5.3 ±0.9

Kidney

Urine

1.1 ±0.3

8.4 ±1.3

Plasma

9.6 ±2.5

11.8 ±6.5

10.9 ±8.1

39.0 ±5.6

Prostate

30 min

% Recovery
5 min

Liver

Total

Distribution of 10% C4- % Injected Dose Recovered (Mean ±SD)
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9.9±1.2

10% C4

10.2±1.8

10.5±0.2

1% C4

10% C4

7.6±0.2

7.8±0.3

7.8±0.4

7.2±0.2

7.2±0.1

6.7±0.7

RBC
(10^6/µl)

13.9±0.9

14.3±0.3

14.8±0.5

14.2±0.5

13.9±0.2

13.3±1.4

HGB
(g/dl)

42.9±2.1

44.1±0.9

46.2±2.0

43.0±0.9

42.4±1.1

40.2±4.2

HCT
(%)

1005±826

1177±202

1001±91

921±475

1023±165

889±252

PLT
(10^3/µl)

[WBC-White Blood Cells; RBC-Red Blood Cells; HGB-Hemoglobin; HCT-Hematocrit; PLT-Platelets]

11.9±0.8

Control

DAY 14

9.4±4.5

8.8±4.1

1% C4

Control

DAY 1

WBC
(10^3/µl)

Hematology (Mean ±SD) at scheduled termination days 1 and 14
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0.1

10% C4

0.1

0.1

1% C4

10% C4

0.33±0.0

0.36±0.0

0.38±0.0

0.34±0.0

0.39±0.1

0.34±0.1

Cr
(mg/dl)

17.9±2.4

19.6±1.5

19.7±1.6

16.6±0.9

15.1±1.8

13.7±2.0

BUN
(mg/dl)

334±345

90±10

191±151

136±28

137±13

140±31

AST
(mg/dl)

214±233

68±7

174±138

69±8

70±7

67±9

ALT
(IU/L)

271±16

223±50

226±41

257±23

250±33

237±44

ALK PHOS
(IU/L)

6.4±0.2

6.3±0.2

6.3±0.1

5.9±0.3

5.8±0.0

5.5±0.3

T. P.
(IU/L)

4.0±0.2

4.1±0.1

4.1±0.2

3.8±0.1

3.7±0.0

3.5±0.2

ALB
(gm/dl)

2.3±0.1

2.2±0.1

2.2±0.2

2.1±0.1

2.1±0.0

1.9±0.1

[T.BILI – Total Bilirubin; Cr – Creatinine; BUN- Blood Urea Nitrogen; AST-Aspartate Aminotransferase; ALK PHOS- Alkaline Phosphatase; ALB-Albumin; GLOB-Globulin]

0.1

Control

DAY 14

0.1

0.1

1% C4

Control

DAY 1

T. BILI
(mg/dl)

GLOB
(gm/dl)

NIH-PA Author Manuscript

Clinical chemistry (Mean ±SD) at scheduled termination days 1 and 14
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